Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study.

ABSTRACT:

SUBMITTER: Kato K

PROVIDER: S-EPMC12909102 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study.

Kato Koji K Inamoto Yoshihiro Y Kawakita Toshiro T Onishi Yasushi Y Matsuoka Ken-Ichi KI Shiratori Soichi S Ikegame Kazuhiro K Hiramoto Nobuhiro N Toyosaki Masako M Katayama Yuta Y Koga Yuhki Y Murayama Shun S Sasagawa Yuji Y Shindo Mami M Teshima Takanori T Hatake Kiyohiko K Maeda Yoshinobu Y

Bone marrow transplantation 20251126 2

PMID: 41298855

Similar Datasets

Differential gene expression profile correlates with bortezomib responsiveness in steroid-resistant cGVHD

Project description:Nineteen patients with steroid-refractory cGVHD (chronic graft versus host disease) received weekly bortezomib from 2 – 12 months (1.6 mg/m2 q wk x 4 followed by one week of rest). Treatment was well tolerated with no > grade 3 adverse events. Six patients achieved CR or good PR (gPR). Average Rodnan scores decreased from 22.6 ± 12.8 to 5.9 ± 6.2 (p<0.005) for 8 patients with sclerosis who completed > 2 treatments, including one patient with marked healing of suppurating lesions and significantly reduced chronic diarrhea in another. Thus, weekly bortezomib was safe and produced early improvements in some patients with longstanding refractory disease. CR or gPR correlated with a younger age and lower number of involved organs with a severity score of > 2. Based on gene expression array and pathway analyses, High Responders displayed an immune response profile that resembled that of hematopoietic stem cell-transplanted patients without cGVHD. By comparison, Low Responders showed markedly altered gene expressions in both cell-mediated immune response and proinflammatory pathways. Our preliminary findings suggest that bortezomib responsiveness may be predicated by distinct immunopathological manifestations among cGVHD patients. This trial was registered at www.clinicaltrials.gov as NCT01158105.

2017-01-18 | GSE56495 | GEO

Long-term Use of Ibrutinib in Japanese Patients with Steroid Dependent/Refractory cGVHD: Final Analysis of Multicenter Study.

Project description: Not available

| S-EPMC10749732 | biostudies-literature

Sarcoidosis + Follow-up study

Project description:Sarcoidosis + Follow-up 6 month after Keywords = sarcoidosis Keywords = follow-up Keywords: other

2005-01-18 | GSE1907 | GEO